PROS1 and infection: In both prophylactic and therapeutic treatments, MAb cocktails from two antigenic sites on SARS-CoV-2-RBD were shown to synergize and protect against infections in animal models5 and clinical trials38,39, yet extensive mutations in the SARS-CoV-2 S protein could lead to antigenic changes resistant to antibody therapies8,9.